Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Shigeru Saito , Stefan Verheye Added: 1 year ago
Elixir Medical has announced positive results from the BIOADAPTOR RCT trial, comparing DynamX Bioadaptor to Resolute Onyx DES. The trial met its primary endpoint of TLF non-inferiority at 12 months. The bioadaptor demonstrated a TLF rate of 1.8% compared to 2.8% for the stent (p<0.001) and showed improved vessel function and pulsatility. Principal investigators DrShigeru Saito (Shonan Kamakura… View more
Author(s): Jonathon A Leipsic Added: 1 year ago
FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).A 14%… View more
Author(s): Paul Sorajja , Ralph Stephan von Bardeleben , , et al Added: 1 year ago
In this short series of interviews, our faculty discuss the recent TRILUMINATE Pivotal Trial Results. We hear fromone of the lead PI’s on the trial,Dr Paul Sorajja (Abbott Northwestern Hospital, Minneapolis, US), as well as Cardiac Surgeon Dr Vinod Thourani (Piedmont Healthcare, Atlanta, US), Interventionalist Prof Ralph Stephan Von Bardeleben (Heart Valve Centre, Mainz, DE) and Heart… View more
Author(s): Paul Sorajja , Ralph Stephan von Bardeleben , Gilbert Tang , et al Start date: May 11, 2023
Watch On-demand Version Severe tricuspid regurgitation remains an unmet need, given the adverse outcomes and symptom burden associated with it. It is estimated that >70 million people worldwide currently have some degree of tricuspid regurgitation. Until recently, surgical intervention and medical therapy were the main treatment modalities, however, transcatheter repair is now an option for… View more
Author(s): Luca Testa Added: 8 months ago
Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France.In this video interview, Dr Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.Specifically, the 6 to 9… View more
Author(s): Rayyan Hemetsberger Added: 1 year ago
Dr Rayyan Hemetsberger(Medical University of Vienna, AT) led several patient-level analyses of pooled data from the BIOFLOW-II,-IV and -V trials, comparing the Orsiro DES to the Xience DES. In this interview, he presents the results of his analysis for complex vs. non-complex PCI patients. Further insights on other patient level analysis (calcified lesions, atherothrombotic risk patients) and his… View more
Added: 4 months ago
Host, Dr Rasha Al-Lamee, is joined by Dr Luca Testa in this episode to compare the use of scaffolds versus no scaffolds, highlighting key differences. The discussion illuminates the standards and benchmarks that define success in DCB procedures, shedding light on the factors that contribute to favourable outcomes. They will also explain the rationale as to why no perfect results of DCB could be… View more
Research Area(s) / Expertise:

Atrial Fibrillation

Job title: Associate Professor of Medicine; Laureate Chair in Molecular Medicine; Vice Chief, Cardiovascular Section
Dr Stavrakis is a clinical cardiac electrophysiologist and Associate Professor of Medicine at the University of Oklahoma Health Sciences Center. He is also the Director of Cardiovascular Research at the University of Oklahoma. Dr Stavrakis’ research has focused on autonomic modulation for the treatment of arrhythmias and other cardiovascular diseases, in both animal models and humans. The… View more